AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2285326 — intervention group
Group type: COMPARATOR
Intervention: Support group intervention (nonstructured discussions)
Number of subjects: 0
Study 7261411 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejuno-ileal bypass surgery
Number of subjects: 19
Study 7261411 — intervention group
Group type: COMPARATOR
Intervention: Lean matched controls
Number of subjects: 19
Study 31540903 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg daily)
Number of subjects: 84
Study 31540903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 31390907 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin + Ezetimibe
Number of subjects: 1734
Study 31390907 — intervention group
Group type: COMPARATOR
Intervention: Pitavastatin Monotherapy
Number of subjects: 1734
Study 26585728 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency spinal cord stimulation (HFS)
Number of subjects: 12
Study 26585728 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency spinal cord stimulation (LFS)
Number of subjects: 12
Study 24697789 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) program in intervention nursing homes
Number of subjects: 1497
Study 24697789 — intervention group
Group type: COMPARATOR
Intervention: Comparison nursing homes (no QI program)
Number of subjects: 1497
Study 21724681 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week exercise training
Number of subjects: 32
Study 20605316 — intervention group
Group type: EXPERIMENTAL
Intervention: GreenLight HPS 120-W laser vaporization (PVP)
Number of subjects: 120
Study 20605316 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 120
Study 20605316 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TURP and PVP)
Number of subjects: 120
Study 17903266 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist outreach visits on two different topics
Number of subjects: 2900
Study 17903266 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one meetings with a pharmacist
Number of subjects: 2900
Study 17903266 — intervention group
Group type: COMPARATOR
Intervention: Visit supported by 'traditional' information material
Number of subjects: 2900
Study 17903266 — intervention group
Group type: COMPARATOR
Intervention: Visit with 'new' information material
Number of subjects: 2900
Study 17903266 — intervention group
Group type: COMPARATOR
Intervention: No visit/material
Number of subjects: 2900
Study 15616047 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine with 1:400,000 epinephrine
Number of subjects: 20
Study 15616047 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 20
Study 12393307 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 267
Study 12393307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 11057103 — intervention group
Group type: EXPERIMENTAL
Intervention: RANTES concentrations in BALF from s.A (14.4 pg/ml)
Number of subjects: 28
Study 11057103 — intervention group
Group type: EXPERIMENTAL
Intervention: RANTES concentrations in BALF from s.B (10.9 pg/ml)
Number of subjects: 28
Study 11057103 — intervention group
Group type: EXPERIMENTAL
Intervention: RANTES concentrations in BALF from s.A (from upper lobes)
Number of subjects: 28
Study 7586312 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bretylium (4.7 g)
Number of subjects: 302
Study 7586312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (high dose: 1.8 g)
Number of subjects: 302
Study 7586312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (low dose: 0.2 g)
Number of subjects: 302
Study 2302368 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (I-653) at 1.8% inspired concentration
Number of subjects: 10
Study 2302368 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (I-653) at 5.4% inspired concentration
Number of subjects: 10
Study 2302368 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (I-653)
Number of subjects: 10
Study 86040 — intervention group
Group type: EXPERIMENTAL
Intervention: String capsule for duodenal specimen collection
Number of subjects: 0
Study 86040 — intervention group
Group type: COMPARATOR
Intervention: Conventional duodenal tube for duodenal specimen collection
Number of subjects: 0
Study 30698120 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness Training (MT)
Number of subjects: 96
Study 30698120 — intervention group
Group type: COMPARATOR
Intervention: Executive Function Training (EFT)
Number of subjects: 96
Study 30698120 — intervention group
Group type: COMPARATOR
Intervention: No Intervention (NI)
Number of subjects: 96
Study 28878048 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical management (MM)
Number of subjects: 223
Study 28878048 — intervention group
Group type: COMPARATOR
Intervention: Interventional therapy (IT)
Number of subjects: 223
Study 25855755 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K supplementation
Number of subjects: 130
Study 25855755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 23833361 — intervention group
Group type: EXPERIMENTAL
Intervention: Agaricus sylvaticus supplementation (2.1 g/day)
Number of subjects: 46
Study 23833361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 21843336 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry cupping treatment (5 sessions over 2 weeks)
Number of subjects: 50
Study 19853704 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 526
Study 19853704 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 526
Study 17454712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation treatment delivered within a randomized clinical trial
Number of subjects: 0
Study 17454712 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in smoking levels
Number of subjects: 0
Study 17454712 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in nicotine dependence
Number of subjects: 0
Study 17454712 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral symptoms
Number of subjects: 0
Study 17454712 — intervention group
Group type: EXPERIMENTAL
Intervention: Core symptoms of physiological dependence
Number of subjects: 0
Study 14756644 — intervention group
Group type: COMPARATOR
Intervention: Single pulse with Candela Vbeam 595-nm pulsed-dye laser
Number of subjects: 25
Study 14756644 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple stacked pulses (3 or 4) at 1.5-Hz repetition rate
Number of subjects: 25
Study 11125374 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 core transrectal ultrasound guided prostate biopsy
Number of subjects: 244
Study 11125374 — intervention group
Group type: COMPARATOR
Intervention: 12 core transrectal ultrasound guided prostate biopsy
Number of subjects: 244
Study 9753485 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 9 mg once daily for 8 weeks
Number of subjects: 201
Study 9753485 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (PRED) 40 mg once daily for the first 2 weeks tapered to 5 mg/day
Number of subjects: 201
Study 9753485 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD)
Number of subjects: 201
Study 9753485 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (PRED)
Number of subjects: 201
Study 10421972 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion (10% solution)
Number of subjects: 12
Study 10421972 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (5% dextrose)
Number of subjects: 12
Study 2091171 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate ingestion
Number of subjects: 8
Study 2091171 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 8
Study 2091171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 402781 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal disodium cromoglycate (SCG) 40 mg/day
Number of subjects: 49
Study 402781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31810731 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular protocolized screening for asymptomatic CAD (annual or second yearly)
Number of subjects: 0
Study 31810731 — intervention group
Group type: COMPARATOR
Intervention: No further screening for asymptomatic CAD
Number of subjects: 0
Study 31488762 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine + ASA (100 mg)
Number of subjects: 40
Study 31488762 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram + Placebo
Number of subjects: 40
Study 31488762 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 40
Study 27912213 — intervention group
Group type: EXPERIMENTAL
Intervention: PLGA/HA grafts
Number of subjects: 8
Study 27912213 — intervention group
Group type: COMPARATOR
Intervention: DBB grafts
Number of subjects: 8
Study 26031187 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron treatment identified by IT method
Number of subjects: 251
Study 26031187 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron treatment identified by VT method
Number of subjects: 251
Study 23358972 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib plus FOLFIRI (37.5 mg per day, schedule 4/2)
Number of subjects: 768
Study 23358972 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI
Number of subjects: 768
Study 23358972 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib plus FOLFIRI
Number of subjects: 768
Study 21208106 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg, three times daily for 2 weeks
Number of subjects: 0
Study 21208106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20074435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ai Chi
Number of subjects: 81
Study 20074435 — intervention group
Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 81
Study 16449866 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous training (n=14, 50% peak work rate)
Number of subjects: 29
Study 16449866 — intervention group
Group type: COMPARATOR
Intervention: Interval training (n=10, 100% peak work rate for 30 s, alternating with rest for 30 s)
Number of subjects: 29
Study 15607042 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 1570
Study 11327193 — intervention group
Group type: EXPERIMENTAL
Intervention: Timeline Followback (TLFB) method
Number of subjects: 34
Study 9597554 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1.0 mg)
Number of subjects: 16
Study 9597554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8186343 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine 2 g daily
Number of subjects: 374
Study 8186343 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalamine 4 g daily
Number of subjects: 374
Study 8186343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 2916297 — intervention group
Group type: EXPERIMENTAL
Intervention: New urinary drainage system with PVP‐I release
Number of subjects: 109
Study 2916297 — intervention group
Group type: COMPARATOR
Intervention: Standard closed drainage system
Number of subjects: 109
Study 31701562 — intervention group
Group type: EXPERIMENTAL
Intervention: OHS education at school
Number of subjects: 1339
Study 31701562 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety training at work
Number of subjects: 1339
Study 31701562 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of OHS education
Number of subjects: 1339
Study 31701562 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of safety training
Number of subjects: 1339
Study 31701562 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequacy in safety training
Number of subjects: 1339
Study 31599044 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation in 30cc to 80cc prostates (WATER trial)
Number of subjects: 217
Study 31599044 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation in 80cc to 150cc prostates (WATER II trial)
Number of subjects: 217
Study 28338038 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based dental sealant (light polymerised resin-based sealant with fluoride)
Number of subjects: 276
Study 28338038 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 276
Study 25921849 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA-rich drinks
Number of subjects: 30
Study 25921849 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA + LC n-3 PUFA
Number of subjects: 30
Study 25921849 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion with SFA + LC n-3 PUFA
Number of subjects: 30
Study 23150274 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad-state condition
Number of subjects: 0
Study 23150274 — intervention group
Group type: COMPARATOR
Intervention: Neutral-state condition
Number of subjects: 0
Study 23150274 — intervention group
Group type: COMPARATOR
Intervention: Disgust condition
Number of subjects: 0
Study 21224369 — intervention group
Group type: EXPERIMENTAL
Intervention: PK-guided docetaxel dosing
Number of subjects: 30
Study 21224369 — intervention group
Group type: COMPARATOR
Intervention: Body surface area-based docetaxel dosing
Number of subjects: 30
Study 18996055 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly detected AF during the first 3 months of implant (4% incidence, 45 of 1170 patients with no AF)
Number of subjects: 1530
Study 18996055 — intervention group
Group type: EXPERIMENTAL
Intervention: History of AF at the time of ICD implant
Number of subjects: 1530
Study 18996055 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly detected AF
Number of subjects: 1530
Study 16868887 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized treatment for 16 weeks
Number of subjects: 24
Study 16868887 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 healthy age- and BMI-matched subjects)
Number of subjects: 24
Study 12771395 — intervention group
Group type: EXPERIMENTAL
Intervention: Activating intervention
Number of subjects: 192
Study 12771395 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 192
Study 11273473 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 29
Study 11273473 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 29
Study 9359118 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 51
Study 9359118 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 51
Study 9359118 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both medications
Number of subjects: 51
Study 9359118 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 51
Study 9359118 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar II disorder
Number of subjects: 51
Study 9359118 — intervention group
Group type: EXPERIMENTAL
Intervention: History of rapid cycling
Number of subjects: 51
Study 1288281 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual packages of support aimed at enhanced social contacts (experimental group, n = 261)
Number of subjects: 523
Study 1288281 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 262)
Number of subjects: 523
Study 3980805 — intervention group
Group type: EXPERIMENTAL
Intervention: Duo formula group treatment (DFGT), facilitated by a fellow sufferer and a physician, in a series of ten 2-hour weekly sessions.
Number of subjects: 0
Study 3980805 — intervention group
Group type: EXPERIMENTAL
Intervention: Duo formula group treatment (DFGT)
Number of subjects: 0
Study 31370912 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU)
Number of subjects: 731
Study 29231073 — intervention group
Group type: EXPERIMENTAL
Intervention: EPs 7630
Number of subjects: 199
Study 29231073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 26951352 — intervention group
Group type: EXPERIMENTAL
Intervention: C. psittaci real-time polymerase chain reaction (PCR)
Number of subjects: 147
Study 25376395 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA > 10 of 200-300 min per week
Number of subjects: 260
Study 25376395 — intervention group
Group type: EXPERIMENTAL
Intervention: LPA
Number of subjects: 260
Study 25376395 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA > 10 and LPA
Number of subjects: 260
Study 23137503 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor treatment
Number of subjects: 4295
Study 23137503 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel treatment
Number of subjects: 4295
Study 23137503 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cystatin C concentration
Number of subjects: 4295
Study 23137503 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge cystatin C concentration
Number of subjects: 4295
Study 23137503 — intervention group
Group type: EXPERIMENTAL
Intervention: One month cystatin C concentration
Number of subjects: 4295
Study 20127870 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI and ERP measures of face-selectivity
Number of subjects: 0
Study 20127870 — intervention group
Group type: COMPARATOR
Intervention: OFA response
Number of subjects: 0
Study 18603731 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa bean husk extract (CBHE) mouth rinse
Number of subjects: 0
Study 18603731 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse
Number of subjects: 0
Study 15853108 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical-cured Panavia 21
Number of subjects: 24
Study 15853108 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-cured RelyX-ARC
Number of subjects: 24
Study 15853108 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical-cured RelyX (resin-modified glass-ionomer cement)
Number of subjects: 24
Study 15853108 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue loading (10^6 load cycles)
Number of subjects: 24
Study 15853108 — intervention group
Group type: COMPARATOR
Intervention: Control (no fatigue loading)
Number of subjects: 24
Study 12429189 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-digit grasping in PD patients
Number of subjects: 9
Study 12429189 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-digit grasping in PD patients with action tremor (AT)
Number of subjects: 9
Study 12429189 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 9
Study 10490156 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg fentanyl in 20 ml saline
Number of subjects: 69
Study 10490156 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg morphine in 20 ml saline
Number of subjects: 69
Study 10490156 — intervention group
Group type: COMPARATOR
Intervention: 20 ml saline (control)
Number of subjects: 69
Study 8959630 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeline Solo (FS, twin-bag)
Number of subjects: 63
Study 8959630 — intervention group
Group type: COMPARATOR
Intervention: Basic Y (BY, single-bag)
Number of subjects: 63
Study 1822216 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem preparations
Number of subjects: 12
Study 6309993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate (10 mg Sb/kg per dose) every 12 hr for 15 days (group B)
Number of subjects: 29
Study 6309993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate (10 mg Sb/kg per dose) administered once daily for 31 days (group A)
Number of subjects: 29
Study 6309993 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate (10 mg Sb/kg per dose) every 8 hr for 10 days (group C)
Number of subjects: 29
Study 31271585 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise program (12 weeks, 2 sessions/week, 45 min/session, low intensity)
Number of subjects: 16
Study 29260804 — intervention group
Group type: EXPERIMENTAL
Intervention: NTP (nonthermal plasma of hexamethyldisiloxane (HMDSO) associated with argon for 30 min)
Number of subjects: 12
Study 29260804 — intervention group
Group type: EXPERIMENTAL
Intervention: HF + S (10% hydrofluoric acid gel for 60 s and silane for 60 s)
Number of subjects: 12
Study 29260804 — intervention group
Group type: EXPERIMENTAL
Intervention: S (70% alcohol and silane for 60 s)
Number of subjects: 12
Study 29260804 — intervention group
Group type: COMPARATOR
Intervention: Co (control, no surface treatment)
Number of subjects: 12
Study 27604792 — intervention group
Group type: COMPARATOR
Intervention: Education-only intervention (1 onsite education session and distribution of the ART)
Number of subjects: 586
Study 27604792 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (2 or more onsite education sessions, distribution of the ART, audit and feedback, barrier identification, site-specific strategy development, promotion of interdisciplinary teamwork, opinion leaders and reminders)
Number of subjects: 586
Study 27604792 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention assessment
Number of subjects: 586
Study 24934963 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg plus adapalene 0.1%/benzoyl peroxide 2.5% gel (D+A/BPO)
Number of subjects: 266
Study 24934963 — intervention group
Group type: COMPARATOR
Intervention: Oral isotretinoin (ISO)
Number of subjects: 266
Study 23019316 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 119
Study 23019316 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 119
Study 23019316 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic and Resistance Training (AT/RT)
Number of subjects: 119
Study 23019316 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Aerobic and Resistance Training (AT/RT)
Number of subjects: 119
Study 19602518 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual dose of rFSH (50-100 IU/day)
Number of subjects: 228
Study 19602518 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of rFSH (75 IU/day)
Number of subjects: 228
Study 17888161 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored worksite health promotion programme with access to an individual Health Portal (features include computer-tailored advice, monitoring function, personal coach, and opportunities to contact professionals).
Number of subjects: 0
Study 17888161 — intervention group
Group type: COMPARATOR
Intervention: Standard worksite health promotion program (control group).
Number of subjects: 0